絞り込み

16501

広告

Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.

著者 Bundhun PK , Janoo G , Teeluck AR , Huang F
BMC Pharmacol Toxicol.2017 Oct 23 ; 18(1):66.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (56view , 0users)

Full Text Sources

Vildagliptin and pioglitazone/rosiglitazone are emerging Oral Hypoglycemic Agents (OHAs) which are used to treat patients suffering from Type 2 Diabetes Mellitus (T2DM). In this analysis, we aimed to systematically compare the adverse drug events which were observed with the use of vildagliptin versus pioglitazone or rosiglitazone respectively.
PMID: 29058622 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード